There’s plenty of evidence that drug development is broken. The estimated efficacy rate of drugs for many common illnesses comes in at 50% or below, and a recent Forbes article by Matt Herper suggests the cost of bringing a new drug to patients is twice the already-big-number commonly used – over $4 billion per drug.
Patients need better.
The Lilly Clinical Open Innovation team exists to make it better. We believe that Open Innovation models – focused on clinical drug development – can result in transformational gains in value-to-patients and efficiency.
We also believe that open data, linked, crowdsourced, consumed and curated by experts outside (as well as inside) the walls of pharma will bring innovative insights and wisdom. And that open communities will set and meet objectives to reduce costs and improve outcomes.
We’ll explore challenge driven innovation and gamification to tap into expertise which might otherwise be missed. We embrace open source development to maximize technical contribution and benefit, and will Work Out Loud to assure transparency on our projects. To manage rights in a distributed digital age we leverage Creative Commons licensing. In the open, with no strings attached.
That’s a lot of buzzwords, and even more to actually try to do. Too much for the smallish Lilly COI group for sure – but that’s kind of the point. Open Innovation promises that we can all play bigger than we are, and enables greater innovation than any individual or organization can accomplish on it’s own.
To start, Clinical Collections is a tool to make personal collections of clinical trials. You can search and filter data served up from Clinicaltrial.gov and save a resulting collection. Collections are presented in multiple views focused on summary, outcomes, timeline and location.
Near term plans include more flexibility to add trials to a collection, as well as a “follow” feature to notify you and others of changes to your collection. Feedback is most welcomed, both on Clinical Collections today as well as how to evolve the tool to meet additional needs.
We’ve bundled Clinical Collections with an open source Q&A tool, and offer up what we call a “disease commons,” focused on Tuberculosis. TB Commons enables sharing of clinical objects – in this case clinical trial collections – and encourages open scientific and operational collaboration focused on disease.
Does the notion of disease commons make sense? We don’t know for sure, and look to understand through experience whether it does. Take a look and share what you think.
Finally, we invite you to join in the journey. We promise honesty, transparency and a passion to make drug development better. We ask the same of you and welcome your participation.